A phase 2 trial of ANAVEX 2-73 in Parkinson's disease
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2018
At a glance
- Drugs ANAVEX 2-73 (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors Anavex Life Sciences
- 07 Feb 2018 According to an Anavex media release, clinical site validation for this trial has been completed.
- 11 Dec 2017 According to an Anavex media release, company plans to file an clinical trial application (CTA) with European regulatory authorities to conduct this trial.
- 10 Feb 2016 New trial record